Foxhollow Technologies Inc

Foxhollow Technologies — Merger or Acquisition (July 2007)

29 slides from Foxhollow Technologies's merger presentation, Jul 23, 2007

  1. Slide 1: Creating a Global Leader in Endovascular Devices

    1 CREATING A GLOBAL CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES LEADER IN ENDOVASCULAR DEVICES Webcast Presentation July 23, 2007

  2. Slide 2: Forward-Looking Statements

    2 This presentation contains “forward-looking statements” about ev3 and FoxHollow within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the benefits of the business combination transaction involving ev3 and FoxHo

  3. Slide 3: Forward-Looking Statements (continued)

    3 The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward- looking statement: general business and economic conditions; the ability to obtain governmental approvals of the transaction on a timely

  4. Slide 4: Presenters

    4 Dr. John Simpson Founder and CEO FoxHollow Technologies Duke Rohlen President of Strategic Operations FoxHollow Technologies Presenters Presenters Jim Corbett President and CEO ev3 Pat Spangler CFO and Treasurer ev3 Dr. John Simpson Founder and CEO FoxHollow Technologies Duke Rohlen President of S

  5. Slide 5: Jim Corbett, President and CEO, ev3

    5 Jim Corbett President and CEO ev3

  6. Slide 6: Transaction Overview

    6 Fourth Quarter of 2007 FoxHollow stockholders, customary closing conditions and anti- trust clearance, including HSR Warburg Pincus and The Vertical Group, together owning 56.8% of ev3 shares, have approved ev3’s issuance of shares in connection with the transaction and the amendment to ev3’s amen

  7. Slide 7: Creating a Global Leader in Endovascular Device Market

    7 Creates broad competitive position in the growing markets for peripheral vascular and neurovascular products Complementary product offering Leveraging combined experienced sales force Capitalizing on global markets Combined product portfolio will have wide spectrum of endovascular treatments for p

  8. Slide 8: Powerful Strategic Logic

    8 Driving revenue growth by increased scope and scale Brings together two experienced sales forces with well-established relationships to leverage selling opportunities Enhanced R&D and clinical research to bring products to market faster Ability to leverage infrastructure to drive profitability gai

  9. Slide 9: Powerful Financial Logic

    9 Significant Revenue Synergies 2008 revenue of $585-$615 million; EPS of $0.60 - $0.70* 2009 revenue of $700-750 million; EPS of $0.90 - $1.10* Market capitalization of $1.7 billion Projected cost savings in excess of $40 million per year Expense reductions in most cost categories Enhanced profitab

  10. Slide 10: Slide 10

  11. Slide 11: Slide 11

  12. Slide 12: Slide 12

  13. Slide 13: Slide 13

  14. Slide 14: Slide 14

  15. Slide 15: Slide 15

  16. Slide 16: Slide 16

  17. Slide 17: Slide 17

  18. Slide 18: Slide 18

  19. Slide 19: The Peripheral Market Opportunity

    10 Carotid Renals Iliac Tibial/ Lower Leg SFA ev3 Participation 2003 Total Market: $2B >10% ev3 Participation 60% 2005 Total Market: $2.5B 70% Combined Company Participation The Peripheral Market Opportunity The Peripheral Market Opportunity Carotid Carotid Renals Renals Iliac Iliac Tibial/ Lower Le

  20. Slide 20: Diverse Endovascular Product Offering

    11 Thrombectomy Removal System * Pending 510(k) approval Diverse Endovascular Product Offering Diverse Endovascular Product Offering Best-in-Class Solutions For Peripheral Vascular Disease Stents Everflex Everflex Long Nanoflex* Primus Protégé Rx Protégé Biggs PTA .014 .018 .035 Longs and large diam

  21. Slide 21: Dr. John Simpson, Founder and CEO, FoxHollow Technologies

    12 Dr. John Simpson Founder and CEO FoxHollow Technologies Dr. John Simpson Founder and CEO FoxHollow Technologies

  22. Slide 22: FoxHollow Product Overview

    13 Product Overview: SilverHawk: Received 510(k) clearance in June 2003 and commenced a formal launch in early 2004 SilverHawk SXL: Recently launched line extension with increased tissue collection capacity TurboHawk: Allows for increased collection capacity and reduced procedure time RockHawk: Curr

  23. Slide 23: ev3 is the Ideal Partner for FoxHollow

    14 ev3’s infrastructure and product breadth is a complementary fit for FoxHollow ev3’s strong international distribution networks can bring FoxHollow’s SilverHawk technology to markets outside the U.S. Combination of FoxHollow’s innovative technologies with ev3’s broader product line creates a compr

  24. Slide 24: Jim Corbett, President and CEO, ev3

    15 Jim Corbett President and CEO ev3

  25. Slide 25: Guidance: Revenues and Projected EPS

    16 Revenues: 2008: In the range of $585-$615 million 2009: In the range of $700-$750 million Projected EPS*: 2008: In the range of $0.60 - $0.70 2009: In the range of $0.90 - $1.10 Including the impact of new and existing amortization expense, excluding the impact of one-time costs related to the tr

  26. Slide 26: Additional Information About the Proposed Transaction

    17 This communication is being made in respect of the proposed business combination involving ev3 and FoxHollow. In connection with the proposed transaction, ev3 intends to file with the SEC a registration statement on Form S-4, containing an information/proxy statement- prospectus and other relevan

  27. Slide 27: Participants in the Solicitation

    18 ev3, FoxHollow and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of FoxHollow in respect of the proposed transaction. Information regarding ev3’s directors and executive officers is availab

  28. Slide 28: Non-GAAP Financial Measures

    19 In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), ev3 uses the non-GAAP financial measures, such as “adjusted EPS” as supplemental measures of performance and believes these measures facilitate operating performance comparisons from

  29. Slide 29: Creating a Global Leader in Endovascular Devices

    20 CREATING A GLOBAL CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES LEADER IN ENDOVASCULAR DEVICES Webcast Presentation July 23, 2007

Foxhollow Technologies — Merger or Acquisition (July 2007) on 6ix